Mantle cell lymphoma: Non-myeloablative versus dose-intensive therapy

Leukemia and Lymphoma

Volumn 44, Issue SUPPL. 3, 2003, Pages

  Hagemeister, Frederick B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CHOP stem cell transplantation; Hyper CVAD MTX AraC stem cell transplantation; Mantle cell lymphoma; Rituximab chemotherapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IODINE 131; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TOSITUMOMAB; VINCRISTINE;

ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT INFECTION; RIGOR; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL;

EID: 1042280334     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001623720     Document Type: Article

References (29)

1. Weisenburger, D.D. and Armitage, J.O. (1996) "Mantle cell lymphoma - an entity comes of age", Blood, 87, 4483-4494.
2. Velders, G.A., Kluin-Nelemans, J.C., De Boer, C.J., Hermans, J., Noordijk, E.M., Schuuring, E., et al. (1996) "Mantle-cell lymphoma: a population-based clinical study", Journal of Clinical Oncology, 14, 1269-1274.
3. Hiddemann, W., Unterhalt, M., Herrmann, R., Woltjen, H.H., Kreuser, E.D., Trumper, L., et al. (1998) "Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group", Journal of Clinical Oncology, 16, 1922-1930.
4. Williams, M.E., Swerdlow, S.H., Rosenberg, C.L. and Arnold, A. (1993) "Chromosome 11 translocation breakpoints at the PRAD 1 cyclin gene locus in centrocytic lymphoma", Leukemia, 7, 241-245.
5. Rosenberg, C.L., Wong, E., Petty, E.M., Bale, A.E., Tsujimoto, Y., Harris, N.L. et al. (1991) "PRAD 1, a candidate BCL-1 oncogene: mapping and expression in centrocytic lymphoma", Proceedings of the National Academy of Sciences of the United States of America, 88, 9538-9642.
6. Dreyling, M.H. and Hiddemann, W. (1999) "Prognostic factors in mantle cell lymphoma: clinical characteristics, pathology, and cell proliferation", Proceedings of the American Society for Clinical Oncology, 18, 3a [abstract].
7. Fisher, R.I., Dahlberg, S., Nathwani, B.N., Banks, P.M., Miller, T.P. and Grogan, T.M. (1995) "A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories: A Southwest Oncology Group study", Blood, 85, 1075-1082.
8. Majlis, A., Pugh, W.C., Rodriguez, M.A., Benedict, W.F. and Cabanillas, F. (1997) "Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants", Journal of Clinical Oncology, 15, 1664-1671.
9. Berger, F., Felman, P., Sonet, A., Salles, G., Bastion, Y., Bryon, P.A., et al. (1994) "Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome", Blood, 83, 2829-2835.
10. Zucca, E., Roggero, E., Pinotti, G., Pedrinis, E., Cappella, C., Venco, A. et al. (1995) "Patterns of survival in mantle cell lymphoma", Annals of Oncology, 6, 257-262.
11. Teodorovic, I., Pittaluga, S., Kluin-Nelemans, J.C., Meerwaldt, J.H., Hagenbeek, A., van Glabbeke, M., et al. (1995) "Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes", European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. Journal of Clinical Oncology, 13, 2819-2826.
12. Bosch, F., Lopez-Guillermo, A., Campo, E., Ribera, J.M., Conde, E., Piris, M.A., et al. (1998) "Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors", Cancer, 82, 567-575.
13. Oinonen, R., Franssila, K., Teerenhovi, L., Lappalainen, K. and Elonen, E. (1996) "Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients", European Journal of Cancer, 34, 329-336.
14. Zhou, L.J. and Tedder, T.F. (1995) CD20 workshop panel report. In Leucocyte Typing V: White Cell Differentiation Antigens - Proceedings of the Fifth International Workshop and Conference, Boston, MA, 3-7 November 1993, edited by S.F. Schlossman, L. Boumsell and W. Gilks et al. Pp. 511-514. Oxford: Oxford University Press.
15. Tedder, T.F. and Engel, P. (1994) "CD20: a regulator of cell-cycle progression of B lymphocytes", Immunology Today, 15, 450-454.
16. Shan, D., Ledbetter, J.A. and Press, O.W. (1998) "Apoptosis of malignant B cells by ligation of CD20 with monoclonal antibodies", Blood, 91, 1644-1652.
17. Foran, J.M., Rohatiner, A.Z., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., et al. (2000) "European phase II study of rituximab (chimeric anti-CD20 monocolonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma", Journal of Clinical Oncology, 18, 317-324.
18. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., et al. (1998) "Rituximab (anti-CD20 monocolonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study", Blood, 92, 1927-1932.
19. Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. et al. (2002) "Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival", Journal of Clinical Oncology, 20, 1288-1294.
20. Andersen, N.S., Donovan, J.W., Burns, J.S., Poor, C.M., Neuberg, D., Aster, J.C., et al. (1997) "Failure of purging in mantle cell lymphoma assessed by polymerase chain reaction of minimal residual disease", Blood, 90, 4212-4221.
21. Khouri, I.F., Romaguera, J., Kantarjian, H., Palmer, J.L., Pugh, W.C., Korbling, M., et al. (1998) "Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle cell lymphoma", Journal of Clinical Oncology, 16, 3803-3809.
22. Khouri, I.F., Lee, M.S., Romaguera, J., Mirza, N., Kantarjian, H., Korbling, M., et al. (1999) "Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy", Annals of Oncology, 10, 1293-99.
23. Khouri, I.F., Saliba, R., Hosing, C., Korbling, M., Younes, A., Romaguera, J., et al. (2002) "Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma", Annals of Oncology, 13, 78 [abstract 262].
24. Hiddemann, W., Dreyling, M., Pfreundschuh, M., Gisselbrecht, C., Diehl, V., Boiron, J.-M., et al. (2001) "Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL) - results of a prospective randomized European Intergroup Study", Blood, 98, 861a [abstract 3572].
25. Romaguera, J.E., Khouri, I.F., Kantarjian, H.M., Hagemeister, F.B., Rodriguez, M.A., McLaughlin, P., et al. (2000) "Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients", Leukemia & Lymphoma, 39, 77-85.
26. Romaguera, J.E. (2001) "Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma", Biological Therapy of Lymphoma, 4, 9-12.
27. Romaguera, J., Cabanillas, F., Dang, N.H., Goy, A., Hagemeister, F.B., Fayad, L., et al. (2001) "Mantle cell lymphoma (MCL) - high rates of complete remission (CR) and prolonged failure-free survival (FFS) with Rituxan-HyperCVAD (R-HCVAD) without stem cell transplant (SCT)", Blood, 98, 726a [abstract 3030].
28. Gopal, A.K., Petersdorf, S., Maloney, D., Eary, J., Wood, B., Rajendran, J., et al. (2001) "High-dose I-131-anti CD-20 antibody therapy (tositumomab), etoposide, cyclophosphamide and autologous stem cell transplantation for patients with relapsed or refractory mantle cell lymphoma", Proceedings of the American Society for Clinical Oncology, 20, 280a [abstract 118].
29. Cohen, B.J., Hedrick, E., Moskowitz, C., Straus, D. and Zelentz, A. (2000) "The cyclophosphamide/fludarabine (CF) regimen in mantle cell lymphoma (MCL)", Proceedings of the American Society for Clinical Oncology, 19, 15a [abstract 50].